New Product Newswire for March 22, 2004
FDA Approves Generic Liraglutide for Type 2 Diabetes
As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
FDA Approves Gepotidacin for Uncomplicated UTI
The decision makes the therapy the first oral antibiotic treatment approved for uUTIs in over 20 years.
FDA Approves Vutrisiran For Adult Patients With ATTR-CM
The decision makes the RNAi therapeutic the only therapy approved by the FDA to treat ATTR-CM and hATTR-PN.
FDA Approves Losartan Potassium for Reduction in Risk of Stroke
The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.
FDA Approves Omalizumab-Igec as First Interchangeable Biosimilar to Xolair
Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.
Mobile Health Technologies to Change Landscape of Cardiovascular Health
Assertive Self-Expression Crucial in Community Pharmacist Deprescribing
Meeting Preview: AAP 2025 Annual Conference
CDC Reports 607 Cases of Measles Across 22 States, Confirming 6 Outbreaks
